Apexigen, Inc.

Apexigen, Inc. (Nasdaq: APGN) is a clinical-stage biopharmaceutical company focused on oncology, specifically the development of antibody-based cancer immunotherapies. The company went public through a merger with Brookline Capital Acquisition Corp, a SPAC sponsored by Brookline Capital Markets that completed its IPO in 2021. The de-SPAC transaction closed in 2022, bringing Apexigen onto Nasdaq under the APGN ticker. The August 2023 Form 8-K filing reflects a late-stage corporate development as the company navigated challenging capital conditions in the post-merger biotech environment. For complete filing history, status updates, and sponsor data on Apexigen and hundreds of other SPAC transactions, sign up for full access at SpacDesk.